Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Nationwide Children's Hospital: Clinical Trials & FDA Approval Profile

Nationwide Children's Hospital (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (12 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.0%
Median Closed Enrollment vs National (145 pts)43 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Nationwide Children's Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)15 (12)
Completed vs Stopped Early4 / 1 (5.0%)
Median Closed Actual Enrollment43 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Nationwide Children's Hospital
Hospital Research SiteLocationShared Protocols
Nationwide Children's HospitalColumbus, OH19
Children's National Medical CenterWashington D.C, DC8
Children's Hospital ColoradoAurora, CO8

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Nationwide Children's Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05286788MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaPhase IIRECRUITING
NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantPhase IIRECRUITING
NCT05267821Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODSPhase II/IIIRECRUITING
NCT05096481PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaPhase IIRECRUITING
NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Nationwide Children's Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI